Your contact persons
CHEPLAPHARM Arzneimittel GmbH
12/01/2022
Change in the Management of CHEPLAPHARM
11/29/2022
CHEPLAPHARM remains on growth track
10/25/2022
CHEPLAPHARM receives growth capital of €550 Million from two leading global investors
08/29/2022
CHEPLAPHARM increases revenue and earnings in the first half of 2022
06/01/2022
CHEPLAPHARM strengthens its oncology portfolio
05/16/2022
CHEPLAPHARM acquires rights to CMV medicine
04/29/2022
CHEPLAPHARM continues profitable growth track in 2021 as well
03/21/2022
Significant and sustainable site expansion
03/01/2022
CHEPLAPHARM acquires additional oncology drugs
Back
